Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | NOS2 | P35228 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.57 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
| ▸ | CCR1 | P32246 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | KDM1A | O60341 | 2/20 | 0.51 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10566099 | 0.92 | MEN1 (0.53) | CHRM4MEN1KMT2ANPSR1NOS2 | |
| SCHEMBL8696969 | 0.91 | RORC (0.58) | CHRM4MEN1KMT2ANPSR1NOS2 | |
| SCHEMBL19458995 | 0.91 | ACE2 (0.56) | CHRM4MEN1KMT2ANPSR1NOS2 | |
| SCHEMBL15379133 | 0.91 | NOS2 (0.54) | CHRM4MEN1KMT2ANPSR1NOS2 | |
| SCHEMBL16936275 | 0.91 | CCR1 (0.64) | CHRM4MEN1KMT2ANPSR1NOS2 | |
| SCHEMBL751049 | 0.90 | OPRD1 (0.53) | CHRM4MEN1KMT2ANPSR1NOS2 | |
| SCHEMBL23859674 | 0.89 | SMN1; SMN2 (0.56) | CHRM4MEN1KMT2ANPSR1NOS2 | |
| SCHEMBL8315425 | 0.89 | OPRD1 (0.54) | CHRM4MEN1KMT2ANPSR1NOS2 | |
| SCHEMBL2265088 | 0.88 | MEN1 (0.69) | CHRM4MEN1KMT2ANPSR1NOS2 | |
| SCHEMBL2885113 | 0.88 | NOS2 (0.61) | CHRM4MEN1KMT2ANPSR1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020137664-A1 | Substituted piperidines as melanocortin-4 receptor agonists | MERCK & CO., INC. | 2002-09-26 | — | — | US | disclosed |
| US-6350760-B1 | OBESITY, DIABETES, SEXUAL DYSFUNCTION; | MERCK & CO., INC. | 2002-02-26 | — | — | US | disclosed |
| CN-1061977-C | Aryl substituted heterocycles | ZENECA LTD (GB) | 2001-02-14 | — | — | CN | disclosed |
| EP-0630887-B1 | 4-(aryl-substituted)-piperidines as neurokinin receptor antagonists | ZENECA LTD (GB) | 1999-07-28 | — | — | EP | disclosed |
| US-5654299-A | TREATING RESPIRATORY SYSTEM DISORDER (I.E. ASTHMA) WITH NEUROKININ 2 RECEPTOR ANTAGONIST | ZENECA LIMITED (GB) | 1997-08-05 | — | — | US | disclosed |
| CN-1098094-A | The heterocycle that aryl replaces | ZENECA LTD (GB) | 1995-02-01 | — | — | CN | disclosed |
| EP-0630887-A1 | 4-(aryl-substituted)-piperidines as neurokinin receptor antagonists | ZENECA LIMITED (GB) | 1994-12-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137664-A1 | Substituted piperidines as melanocortin-4 receptor agonists | MC4R, MC5R, MC3R | CHRM4 49/4885MEN1 1699/4885KMT2A 1288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.